Key result
Transatrial TMVR achieves ~91% technical success with zero 30-day mortality in severe mitral annular calcification.
Why the study?
Mitral valve replacement in severe mitral annular calcification carries high morbidity and mortality, and transseptal/apical TMVR may not be anatomically feasible, making transatrial TMVR a potential option.
Does transatrial TMVR provide a safe and effective treatment option for high-risk patients with severe mitral annular calcification?
Observational (n=11)
No
Does transatrial TMVR provide a safe and effective treatment option for high-risk patients with severe mitral annular calcification?
Transatrial TMVR is a safe and technically feasible treatment option for patients with severe mitral annular calcification who are at high risk for conventional surgical mitral valve replacement.
Answers are grounded in this paper and cite their sources.
May support transatrial TMVR in select high-risk MAC cases; hypothesis-generating and requires prospective validation before practice change.
OBJECTIVE: Mitral valve replacement (MVR) in the setting of severe mitral annular calcification is a technically challenging operation with increased morbidity and mortality. Transseptal/apical transcatheter MVR (TMVR) in mitral annular calcification has emerged as an option for these cases, although may not be feasible due to anatomical reasons. Transatrial TMVR is a potential treatment option for this subgroup of patients. METHODS: Patients who underwent transatrial TMVR between June 2018 and November 2020 at a single institution were included. Patients were selected by a structural heart team based on their surgical risk, pattern of mitral annular calcification, risk of valve migration, left ventricular outflow obstruction, and paravalvular leak. RESULTS: A total of 11 patients underwent transatrial TMVR. Mean patient age was 74.2 years and mean Society of Thoracic Surgeons predicted risk of mortality score was 9.1%. All patients had the presence of both mitral stenosis and regurgitation-dominant etiology-was mitral stenosis in 81.2%, and mitral regurgitation in 18.8%. Among patients, 54.5% had a concomitant cardiac procedure. There was no in-hospital or 30-day mortality. Technical success defined by the Mitral Valve Academic Research Consortium was achieved in 90.9% of patients. Postoperative paravalvular leak was mild or less in all patients. CONCLUSIONS: In this series, transatrial TMVR was shown to be a safe and effective treatment option for patients who are high risk for surgical MVR and should be in surgeons' armamentarium in the treatment of this high-risk patient population. Dissemination of safe technique will be critical in the successful conduct of this surgery.
No takes yet. Share an insight, caveat, or question.
Kawano et al. (2021) conducted an observational in Severe mitral annular calcification with mitral valve disease (n=11). Transatrial transcatheter mitral valve replacement was evaluated on In-hospital or 30-day mortality. Transatrial transcatheter mitral valve replacement achieved 90.9% technical success with 0% 30-day and in-hospital mortality among 11 high-risk patients with severe mitral annular calcification.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: